ASTMH 2020: Re-starting malaria R&D in the face of COVID in Africa

Tuesday, 17 November 2020, 11:45 – 13:30 GMT
Virtual event

Join our Virtual Sponsored Symposium at the ASTMH 2020 Annual Meeting.

COVID-19 has put a halt to much of the health research happening worldwide. It is vital that malaria R&D and clinical trials are re-started as soon as possible to ensure we do not lose valuable time bringing much needed innovations, such as new drugs and insecticides, to market.

This symposium will share perspectives from research programmes on how COVID-19 has affected their operations and their planning for re-starting R&D in a safe and effective manner.


Mark Chataway, Baird’s CMC


Dr Abdourahmane Diallo, CEO, RBM Partnership to End Malaria

Catherine Kyobutungi, Executive Director, African Population and Health Research Centre

Dr Berhnards Ogutu, Chief Research Officer with the Kenya Medical Research Institute (KEMRI) and Senior Clinical Trialist with the Malaria Clinical Trials Alliance of the INDEPTH-Network

Michael Makanga, Executive Director, European & Developing Countries Clinical Trials Partnership (EDCTP)

Caroline Boulton, Global Programme Head, Malaria, Novartis

Lacina Koné, Director General, Smart Africa

Dr David Reddy, CEO, Medicines for Malaria Venture

Register for this event on the ASTMH website


David Reddy

MMV's CEO Dr David Reddy will be speaking at this event.